Several international guidelines concerning lower extremity arterial disease (LEAD) have been published recently, in particular, by the American Heart Association the European Society of Cardiology/European Society for Vascular Surgery, the European Society for Vascular Medicine and the Society for Vascular Surgery. These guidelines differ in some respects and certain issues are not addressed. The objective of this consensus driven by the French Societies of vascular Medicine and surgery was to analyze the disparities between the different guidelines, as well as certain issues not covered, and develop proposals with regard to these points. The following fields of LEAD have been explored: 1) classifications, 2) clinical evaluation, 3) diagnostic criteria, 4) quantification of arterial stenosis using duplex ultrasound, 5) detection of asymptomatic multisite lesions, 6) screening for LEAD in the context of cardiac disease, 7) medical treatment, 8) supervised exercise therapy, 9) revascularization and revascularization of the internal artery stenosis, 10) management of chronic limb ischemia, 11) longitudinal follow-up, and 12) diet. Limb ischemia with threatened viability related to several factors (neurologic, infectious.). This term was proposed by the ESC and ESVS groups in the guidelines published in 2017. Claudication Pain, cramp, or muscular fatigue of arterial origin, induced by exercise in the active muscle group and relieved by rest (within a few minutes) Maximum walking distance Maximum walking distance in meters before the onset of severe pain precludes further walking. Resting TcPO 2 Transcutaneous oxygen pressure measured at rest Minor amputation Distal amputation preserving the heel LEAD Major amputation Amputation involving loss of the heel LEAD Endovascular treatment Any endoluminal treatment, irrespective of the method used, as opposed to open surgery. Volume 72, April 2021 SFMV/SCVE consensus about LEAD 3 IiA-3. In view of the impact of LEAD on therapeutic strategy, we suggest screening for this Volume 72, April 2021 SFMV/SCVE consensus about LEAD 5 CV, cardiovascular; SCORE, systematic coronary risk estimation; GFR, glomerular filtration rate. Volume 72, April 2021 SFMV/SCVE consensus about LEAD 11 a Proteinuria, renal insufficiency defined by a Glomerular Filtration Rate (GFR) < 30 mL/min/1.73 m 2 , left ventricular hypertrophy, or retinopathy. b Age, hypertension, dyslipidemia, smoking, obesity. Volume 72, April 2021 SFMV/SCVE consensus about LEAD 13 PSV means peak systolic velocity; PSVR means peak systolic velocity ratio. PSVs are expressed in cm/s.